BioSpace News Archive

Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that PNOC022, a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study.

Scipher Medicine ® to Present at the Jeffries London Healthcare Conference

Establishment Labs Holdings Inc. today announced its participation in two upcoming investment conferences.

Cybin Inc. will present virtually at the Jefferies London Healthcare Conference being held virtually November 18-19, 2021.

Quoin Pharmaceuticals Ltd. and Genpharm Services today announced that they have entered into an exclusive License and Distribution Agreement for QRX003, Quoin’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease.

The molecular biology enzymes, kits, and reagents market has been predicted to grow at a significant speed in the incoming years.

The epilepsy monitoring devices market has been estimated to grow at a significant speed in the forthcoming years.

Transparency Market Research has published a new report titled, “Benzodiazepine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Gmax Biopharm announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity.

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided a manufacturing and regulatory update for AXO-Lenti-PD, its clinical-stage gene therapy for Parkinson’s disease.